IRB #

STUDY00019817

Title

A PHASE 3, MULTICENTER, RANDOMIZED,
PLACEBO-CONTROLLED, DOUBLE-BLIND STUDY OF
THE EFFICACY AND SAFETY OF APREMILAST (CC-
10004) IN SUBJECTS WITH MODERATE TO SEVERE
GENITAL PSORIASIS

Principal Investigator

Teri Greiling

Study Purpose

To evaluate the the effectiveness of oral apremilast (study drug) 30 mg twice daily, compared to placebo, in subjects with moderate to severe genital psoriasis.

Medical Condition(s)

Psoriasis

Eligibility Criteria

Must :
Be ≥ 18 years of age
Have a diagnosis of moderate or severe psoriasis of the genital area
Be in good health (except for psoriasis)

Other criteria will be discussed with investigator

Healthy Volunteers Needed

No

Placebo Chance

50% in the first 16 weeks, but 0% after

Duration of Participation

36 weeks

Minors Included

No

Contact

Call our Dermatology clinical trials recruiter at 503-418-9386 or email dermtrials@ohsu.edu

Sponsor

Amgen, Inc.

Recruitment End

12/31/2021

Compensation Provided

No


Go Back